banner
 
bar

program

slides
bar
 
 

New Frontiers and Treatment Advances in Atopic Dermatitis (AD)

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

1.5 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in atopic dermatitis

Release Date

November 5, 2015

Expiration Date

November 5, 2017

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period November 5, 2015 through November, 5 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 5 segments totaling 1.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals

Accreditation Statement

This activity has been planned and implemented in accordance with accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and CMEducation Resources, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Postgraduate Institute for Medicine designates this live activity for a maximum of
1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Program Faculty and Disclosure

THOMAS BIEBER, MD, PhD, MDRA
(Program Chair)

Professor of Dermatology and Allergy
University of Bonn
Director and Chairman
Bonn, Germany

Consultant: Regeneron, Novartis, Pfizer, L’Oreal, Astellas, Bioderma, Galderma
Speaker’s Bureau: Regeneron, Novartis, Pfizer, L’Oreal, Astellas, Bioderma, Galderma


ERIC SIMPSON, MD
Associate Professor
Oregon Health and Science University
Portland, Oregon

Consultant: Regeneron, Genentech, Celgene, Anacor, MedImmune
Grant/Research Support: Galderma, Regeneron, Genentech, Anacor, MedImmune



METTE S. DELEURAN, MD, DMSc
Chairman, Dept. of Dermatology
Aarhus University Hospital
Aarhus, Denmark

Consultant: Meda Pharma, Regeneron, Pierre Fabre Dermo Cosmetique
Grant/Research Support: Abb Vie, Regeneron, Merck



PROF. DR. MED. DR. H.C. ANDREAS WOLLENBERG
Dept. of Dermatology and Allergology
Ludwig-Maximilian University
Munich, Germany

Advisory Board: AMGEN, Anacor, Astellas Pharma, Celgene, Galderma, Glaxo Smith Kline, MedImmune, Merck Pharma, Merck Sharp Dohme, Novartis Pharma, Pfizer, Regeneron, Roche Pharma, Sanofi
Lecture Honoraria: Amgen, Astellas Pharma, Basilea Pharmaceutica, Galderma, Glaxo SmithKline, Hans Karrer, Leo Pharma, L’oreal, MEDA Pharma, Merck Pharma, Merck Sharp Dohme, Novartis Pharma, Pierre Fabre, Roche Pharma, Stiefel, a GSK company
Consultancy Honoraria: Astellas Pharma, Celgene, Celtic Pharma, Hans Karrer, L’Oreal, MedImmune, Merck Pharma, Novartis Pharma, Pierre Fabre
Expert Witness: Merck Pharma
Travel Support: ALK Scherax, Astellas Pharma, Basilea Pharmaceutica, Chugai Pharma, L’Oreal, MEDA Pharma, Novartis Pharma, Pierre Fabre

Program Managers and Web Editor Disclosure

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Program Manager Gideon Bosker, MD has nothing to disclose. Program reviewer Milo Falcon has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Manage patients with moderate-to-severe atopic dermatitis;
  • Apply national and international professional association-based guidelines for assessment and diagnosis of atopic dermatitis to the front line of patient care;
  • Apply national and international professional association-based guidelines for management of atopic dermatitis to the front line of patient care;
  • Detail the epidemiology, disease burden, and quality-of-life dimensions associated with atopic dermatitis based on severity of disease and health care disparities;
  • Sequence and combine non-pharmacologic and pharmacologic therapies based on severity of disease, biomarkers, and guideline-directed roadmaps for optimizing management of atopic dermatitis;

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2015 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC

 
6

 

Key Program Topics Include:

Alefacept
AN2728
anti-IL-4Rα
atopic dermatitis
Azathioprine
Azathioprine
cream in Phase 2

(AstraZeneca)
Cyclosporine
Dupilumab
Efalizumab
effects on the epidermis in AD
IL-17

 

Imuran
JAK inhibitor
Methotrexate
MTX
Mycophenolate mofetil
Mycophenolate Mofetil
NBUVB

PDE4 inhibitors
Probiotics
roflumilast
Th2 Cytokine
Tofacitinib
urticaria
Vitamin D